SEDAR Interim Financial Statements

-1- DIAGNAMED HOLDINGS CORP. INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE-MONTH PERIODS ENDED DECEMBER 31, 2025 AND 2024 (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED) -2- Notice to Reader Under National instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the interim financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor. The accompanying unaudited condensed interim financial statements have been prepared by and are the responsibility of management. The Company’s independent auditor has not performed a review of these condensed interim financial statements in accordance with the standards established by the Chartered Professional Accountants of Canada for a review of the condensed interim financial statements by an entity’s auditor. -3- The accompanying notes are an integral part of these consolidated financial statements. DiagnaMed Holdings Corp. Interim Consolidated Statements of Financial Position (Stated in Canadian Dollars) (Unaudited) December 31, September 30, Notes 2025 2025 ASSETS Current assets Cash and cash equivalents 128,406 $ 183,832 $ Amounts receivable 24,247 17,597 Prepaid expenses 14,656 14,932 TOTAL ASSETS 167,309 $ 216,361 $ LIABILITIES AND EQUITY Current liabilities Trade and other payables 439,955 $ 666,472 $ Total liabilities 439,955 666,472 Shareholders' deficiency Common shares 4 4,532,249 4,276,832 Contributed surplus 5 1,543,894 1,535,444 Deficit (6,348,789) (6,262,387) Total shareholders' deficiency (272,646) (450,111) TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIENCY 167,309 $ 216,361 $ Nature of operations and going concern 1 Approved on behalf of the Board of Directors: "Johnny Karagiannidis" "Ming Jang" Johnny Karagiannidis, Director Ming Jang, Director -4- The accompanying notes are an integral part of these consolidated financial statements. DiagnaMed Holdings Corp. Interim Consolidated Statements of Loss and Comprehensive Loss (Stated in Canadian Dollars) (Unaudited) Notes 2025 2024 Expenses Consulting fees 8 41,093 $ 8,571 $ General and administrative 4,789 8,299 Investor relations 42,782 9,915 Professional fees 3,000 24,220 Research and development - 21,267 Share-base payments 5 8,450 38,619 Loss (gain) on foreign exchange (13,060) 24,000 Loss and comprehensive loss before below items (87,054) (134,891) Other income (expense) Interest income 652 921 Net loss and comprehensive loss for the period (86,402) $ (133,970) $ Weighted average number of common shares outstanding - basic and diluted 113,759,426 80,052,640 Basic and diluted loss per common share (0.00) $ (0.00) $ Three-month periods December 31, ended -5- The accompanying notes are an integral part of these consolidated financial statements. DiagnaMed Holdings Corp. Interim Consolidated Statements of Changes in Shareholders' Deficiency (Stated in Canadian Dollars) (Unaudited) Contributed Number Amount Surplus Deficit Total Balance at September 30, 2024 80,052,640 3,568,686 $ 1,025,389 $ (4,859,242) $ (265,167) $ Common shares issued for debt settlement 1,359,000 67,800 $ - - 67,800 Stock-based compensation - - 38,619 - 38,619 Net loss and comprehensive loss for the period - - - (133,970) (133,970) Balance at December 31, 2024 81,411,640 3,636,486 $ 1,064,008 $ (4,993,212) $ (292,718) $ Balance at September 30, 2025 109,158,973 4,276,832 1,535,444 (6,262,387) (450,111) $ Exercise of warrants 5,108,333 255,417 - - 255,41 --- 7 Restricted Stock Units - - 8,450 - 8,450 Net loss and comprehensive loss for the period - - - (86,402) (86,402) Balance at December 31, 2025 114,267,306 4,532,249 $ 1,543,894 $ (6,348,789) $ (272,646) $ Common Shares -6- The accompanying notes are an integral part of these consolidated financial statements. DiagnaMed Holdings Corp. Interim Consolidated Statements of Cash Flows (Stated in Canadian Dollars) (Unaudited) 2025 2024 Operating activities Net loss for the period (86,402) $ (133,970) $ Adjustments for: Share-based payments 8,450 38,619 Gain on settlement of debt - 20,340 Changes in non-cash working capital items: Amounts receivable (6,650) (13,710) Prepaid expenses 276 3,760 Trade and other payables (226,517) 37,147 Net cash used in operating activities (310,843) (47,814) Financing activity Proceeds from the exercise of warrants 255,417 - Net cash provided by financing activity 255,417 - Change in cash during the period (55,426) (47,814) Cash and cash equivalents, beginning of the period 183,832 162,146 Cash and cash equivalents, end of the period 128,406 $ 114,332 $ Three-month periods December 31, ended DIAGNAMED HOLDINGS CORP. Notes to the Interim Consolidated Financial Statements For the Three-month period Ended December 31, 2025 (Stated in Canadian Dollars) (Unaudited) -7- 1. NATURE OF OPERATIONS AND GOING CONCERN Diagnamed Holdings Corp. ("Diagnamed" or the "Company) was incorporated under the Business Corporations Act (British Columbia) on April 16, 2021. The registered head office of the Company is 82 Richmond Street East, Toronto, ON. M5C 1P1, Canada. On November 8, 2022, the Company's common shares were approved for listing on the Canadian Securities Exchange (the "CSE") and commenced trading under the trading symbol "DMED". The Company is a Canadian technology innovator focused on developing advanced natural hydrogen extraction technologies to support the rapidly growing hydrogen sector. The Company is committed to delivering scalable, cost-efficient, and sustainable solutions essential to global energy security and decarbonization. The development of such technology will also compliment the Company’s generative AI healthcare solutions efforts which is focused on the development and commercialization of BRAIN AGE® BRAIN HEALTH, a proprietary brain health AI platform for the healthcare market. These unaudited condensed interim consolidated financial statements have been prepared using accounting policies in compliance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) on the assumption that the Company will continue as a going concern and realize its assets and discharge its liabilities in the normal course of business rather than through a process of forced liquidation. On December 5, 2025, the Company entered into acquisition agreement to acquire the Colchester East Natural Hydrogen Project in Nova Scotia, consisting of 30 licenses totaling 2,104 claims. The Company will pay $10,000 and will issue 10,000,000 common shares to the sellers, who will also retain a 2% revenue royalty, half of which can be repurchased by the Company for $2 million. The proposed transaction is subject to regulatory approval. As at December 31, 2025, the Company had not yet achieved profitable operations, had an accumulated deficit of $6,348,789 since inception, and expects to incur further losses in the development of its business. These events and conditions indica --- te a material uncertainty that may cast significant doubt on the Company’s ability to continue as a going concern. The Company’s continuation as a going concern is primarily dependent upon its ability to raise financing from equity markets or borrowings and, upon successful results from its business activities. While the Company has been successful in securing financings in the past, there is no assurance that it will be able to do so in the future. Accordingly, these financial statements do not give effect to adjustments, if any, that would be necessary should the Company be unable to continue as a going concern. If the going concern assumption was not used, then the adjustments required to report the Company’s assets and liabilities on a liquidation basis could be material to these financial statements. DIAGNAMED HOLDINGS CORP. Notes to the Interim Consolidated Financial Statements For the Three-month period Ended December 31, 2025 (Stated in Canadian Dollars) (Unaudited) -8- 2. BASIS OF PREPARATION Statement of compliance These unaudited consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") issued by the International Accounting Standards Board (“IASB”) and interpretations issued by the IFRS Interpretations Committee ("IFRIC"). These unaudited consolidated financial statements were approved and authorized for issuance on the date of Board of Directors' approval of February 23, 2026. Basis of measurement These unaudited consolidated financial statements have been prepared on a historical cost basis except for financial instruments classified as financial instruments at fair value through profit or loss, which are stated at their fair value. In addition, these consolidated financial statements have been prepared using the accrual basis of accounting, except for cash flow information. Functional currency and presentation currency These unaudited consolidated financial statements are presented in Canadian (“CDN”) dollars, except as otherwise noted, which is the functional currency of the Company and its subsidiary, Diagnamed Inc. Basis of consolidation These unaudited consolidated financial statements incorporate the financial statements of the Company and its subsidiary. The subsidiary is consolidated from the date of acquisition, being the date on which the Company obtains control, and continues to be consolidated until the date that such control ceases. Control is achieved when an investor has power over an investee to direct its activities, exposure to variable returns from an investee, and the ability to use the power to affect the investor's returns. The results of subsidiary acquired or disposed of during the period presented are included in the consolidated statements of comprehensive loss from the effective date of control and up to the effective date of disposal or loss of control, as appropriate. All intercompany transactions, balances, income and expenses are eliminated upon consolidation. 3. EXPLORATION AND EVALUATION COSTS On May 30, 2025, the Company issued 12,500,000 common shares of the Company for the acquisition of 91 unpatented, single-cell mineral claims, each cell approximately 20 hectares in size, totaling an area of 1,820 hectares, within Ontario’s highly prospective Temiscamingue hydrogen district and graben. Under the terms of the acquisition agreement, the Company is also required to make a non-refundable $25,000 payment. The Company has als --- o granted certain sellers a 2.0-per-cent royalty on revenues from the sale of any hydrogen or other minerals on the property. Fifty per cent of the seller’s royalties may be purchased for $2 million. DIAGNAMED HOLDINGS CORP. Notes to the Interim Consolidated Financial Statements For the Three-month period Ended December 31, 2025 (Stated in Canadian Dollars) (Unaudited) -9- 4. COMMON SHARES a) Authorized An unlimited number of common shares with no par value. b) Issued During the three-month period ended December 31, 2025, the following common shares were issued:  The Company issued 5,108,333 common shares on the exercise of 5,108,333 warrants with an average exercise price of $0.05 per warrant. During the three-month period ended December 31, 2024, the following common shares were issued:  The Company issued 1,359,000 common shares in settlement of accounts payable of $67,800. The transaction resulted in a gain on settlement of debt of $20,340. 5. CONTRIBUTED SURPLUS a) Warrants The changes in warrants during the three-month periods ended December 31, 2025 and 2024 are as follows: Warrants exercisable and outstanding as at December 31, 2025 are as follows: As at December 31, 2025, the weighted average life remaining of warrants outstanding was 1.27 years. Weighted- Weighted- Number of average Number of average warrants exercise price warrants exercise price Balance beginning of period 14,242,360 0.05 $ - - $ exercised (5,108,333) 0.05 - - Balance, December 31, 9,134,027 0.05 $ - - $ Three-month period Three-month period ended ended December 31, 2025 December 31, 2024 Number of Exercise Expiry Date warrants Price April 11, 2027 9,134,027 0.05 $ 9,134,027 $ 0.05¹ ¹Weighted-average exercise price. DIAGNAMED HOLDINGS CORP. Notes to the Interim Consolidated Financial Statements For the Three-month period Ended December 31, 2025 (Stated in Canadian Dollars) (Unaudited) -10- 5. CONTRIBUTED SURPLUS (continued): b) Stock Options: The Company had previously adopted an incentive stock option plan in accordance with the policies of the Exchange (the “Stock Option Plan”). Options may be granted for a maximum term of five years from the date of the grant. They are not transferable. Unless the Board determines otherwise, options shall be exercisable in whole or in part at any time during this period. Options expire within 90 days of termination of employment or holding office as director or officer of the Company and, in the case of death, expire within a maximum period of one year after such death, subject to the expiry date of the option. During the three-month period ended December 31, 2025, there were no stock options granted by the Company. During the three-month period ended December 31, 2024, there were no stock options granted by the Company.  On November 11, 2024, the Company granted 4,500,000 stock options to certain Directors, Officers, and Consultants of the Company with each stock option exercisable into one common share of the Company at an exercise price of $0.05 per share for five years from the date of grant. The options were valued at $150,400 using a Black-Scholes valuation model with the following assumptions: share price of $0.04 per common shares, expected dividend yield of 0%, expected volatility of 183%, risk-free rate of 3.10%, and expected life of 5 years. The changes in stock options outstanding during the three-month periods ended December 31, 2025 and 2024 are as follows: Weighted- Weighted- Number of average Number of --- average options exercise price options exercise price Balance beginning of period 5,675,000 0.05 $ 1,750,000 0.10 $ Granted - - 4,500,000 0.05 Balance, December 31, 5,675,000 0.05 $ 6,250,000 0.06 $ December 31, 2025 December 31, 2024 Three-month period Three-month period ended ended DIAGNAMED HOLDINGS CORP. Notes to the Interim Consolidated Financial Statements For the Three-month period Ended December 31, 2025 (Stated in Canadian Dollars) (Unaudited) -11- 5. CONTRIBUTED SURPLUS (continued): b) Stock Options (continued): Stock options exercisable and outstanding as at December 31, 2025 are as follows: c) Restricted Stock Units During the three-month period ended December 31, 2025, there were no Restricted Stock Units (“RSUs”) granted by the Company. The changes in RSUs outstanding during the three-month periods ended December 31, 2025 and 2024 are as follows: On July 17, 2025, the Company granted 3,000,000 Restricted Stock Units (“RSUs”) as compensation to senior executives of the Company. The share price of the Company was $0.035 per share on the date of the grant. The RSUs will vest as follows: o 1,000,000 RSUs will vest on the first anniversary of the grant date, o 1,000,000 RSUs will vest on the second anniversary of the grant date and, o 1,000,000 RSUs will vest on the third anniversary of the grant date. The Company has valued the prorated vested portion of the RSUs to be $21,635. Number of Exercise Expiry Date options Price January 4, 2027 200,000 0.10 $ July 17, 2028 2,475,000 0.05 November 11, 2029 3,000,000 0.05 5,675,000 $ 0.05¹ ¹Weighted-average exercise price. Number of Weighted- Number of Weighted- RSUs average price RSUs average price Balance beginning of period 3,000,000 0.035 $ - - $ Granted - - - - Balance, December 31, 3,000,000 0.035 $ - - $ Three-month period Three-month period ended ended December 31, 2025 December 31, 2024 DIAGNAMED HOLDINGS CORP. Notes to the Interim Consolidated Financial Statements For the Three-month period Ended December 31, 2025 (Stated in Canadian Dollars) (Unaudited) -12- 6. FINANCIAL INSTRUMENTS AND OBJECTIVES AND POLICIES Risk Management In the normal course of business, the Company is exposed to a number of risks that can affect its operating performance. These risks, and the actions taken to manage them, are as follows: Fair Values The Company has designated its cash as FVTPL which are measured at fair value. Fair value of cash is determined based on transaction value and is categorized as a Level One measurement. Level One - includes quoted prices (unadjusted) in active markets for identical assets or liabilities. Level Two - includes inputs that are observable other than quoted prices included in Level One. Level Three - includes inputs that are not based on observable market data. As at December 31, 2025, the carrying and fair value amounts of the Company's cash are approximately equivalent due to its short-term nature. Credit Risk Credit risk is the risk of loss associated with a counterparty’s inability to fulfill its payment obligations. As at December 31, 2025, management believes that the credit risk with respect to cash and cash equivalents and accounts receivable is minimal. Liquidity Risk Liquidity risk is the risk that the Company will encounter difficulty in satisfying its financial obligations. The Company manages its liquidity risk by forecasting it operations and anticipating its operating and investing activities. As at December 31, 2025, the Company had working capit --- al deficit of $272,646 (FY2025 - $292,718). Interest Risk Interest risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company’s exposure to the risk of changes in market interest rates relates primarily to its cash and cash equivalents. As of December 31, 2025, sensitivity to a plus or minus 5% change in market interest rate would not be material as the Company has a nominal amount held in US cash. Foreign currency risk The Company’s functional and reporting currency is the Canadian dollar. As of December 31, 2025, sensitivity to a plus or minus 10% change in US dollar foreign exchange rate would affect the reported comprehensive loss by approximately $27,000. DIAGNAMED HOLDINGS CORP. Notes to the Interim Consolidated Financial Statements For the Three-month period Ended December 31, 2025 (Stated in Canadian Dollars) (Unaudited) -13- 7. CAPITAL MANAGEMENT The Company objectives when manages its capital is to ensure sufficient financial flexibility to achieve the ongoing business objectives including funding of future growth opportunities, and pursuit of accretive acquisitions and to maximize shareholder return through enhancing the share value. The Company monitors its capital structure and makes adjustments according to market conditions in an effort to meet its objectives given the current outlook of the business and industry in general. The Company may manage its capital structure by issuing new shares, repurchasing outstanding shares, adjusting capital spending, or disposing of assets. The capital structure is reviewed by management and the Board of Directors on an ongoing basis. The Company's ability to continue to carry out its planned activities is uncertain and dependent upon the continued financial support of its shareholders and securing additional financing. The Company considers its capital to be equity, which comprises share capital, warrants, contributed surplus and, accumulated deficit, which at December 31, 2025 totaled deficiency of $272,646 (FY2025 - $450,111). Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. 8. RELATED PARTY TRANSACTIONS Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control or common significant influence, related parties may be individuals or corporate entities. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties. The following is a summary of the related party transactions that occurred during the three-month period ended December 31, 2025 and 2024: 2025 2024 Management fees incurred to a company controlled by the CEO of the Company 19,796 $ - $ Management fees incurred to a company controlled by the CFO of the Company 9,750 - Consulting fees incurred to a director of the Company 11,547 - Management fees incurred to a company that employed the former CFO of the Company - 14,292 Share-based payments 8,450 23,171 Total 49,543 $ 37,463 $ Three-month periods ended December 31, DIAGNAMED HOLDINGS CORP. Notes to the Interim Consolidated Financial Statements For the Three-month --- period Ended December 31, 2025 (Stated in Canadian Dollars) (Unaudited) -14- 9. RESEARCH HYDROGEN DiagnaMed’s cutting-edge hydrogen production technology represents a breakthrough in clean energy. Developed by Dr. Qingwang Yuan of the at Texas Tech University, the patented method combines hydraulic fracturing with electromagnetic wave heating to extract hydrogen from light oil, gas, and shale reservoirs, as well as ultramafic rock formations. BrainTremor™ DiagnaMed is investigating technological applications that monitor, collect and use individual information to detect tremors, and measuring cognitive and brain activity in patients with neurological disorders. BRAIN AGE® Brain Health BRAIN AGE® Brain Health is a brain health AI platform leveraging that aims to predict and monitor brain age and provide actionable insights for mental health and neurodegenerative disorders. 10. COMMITMENTS On June 24, 2021, the Company has entered into a licensing arrangement with the Drexel University relating to the BrainAge™ project, whereby US$2,500 will be paid each year and certain milestone payments and royalties are payable upon the achievement of certain events. The Company will record these amounts as the events occur. On December 8, 2021, the Company entered into a licensing agreement with the University of Colorado relating to certain patents held by the University of Colorado for self-healable, recyclable, reconfigurable and wearable electronics devices. The Company is committed to pay to University of Colorado license fees of US$10,000 on December 8, 2021 (the "Effective Date") and license maintenance fees as follows: US$10,000 on the third anniversary of the Effective Date, US$15,000 on the fourth anniversary of the Effective Date, US$30,000 on the fifth anniversary of the Effective Date, US$50,000 on the sixth anniversary of the Effective Date and $US75,000 on the seventh and subsequent anniversaries of the Effective Date until the termination of the agreement. On April 11, 2023, the license agreement was terminated and there are no further obligations. On November 15, 2022, the Company announced it entered into a license agreement with KU Center for Technology Commercialization, Inc. (“KUTC”), a non-profit corporation of the University of Kansas, for the development and commercialization of intellectual property of a novel virtual reality and artificial intelligence neurodiagnostic system (“VR/AI Neuro”) for the evaluation, diagnosis and monitoring of neurodegenerative diseases, such as Parkinson’s disease. The Company paid to KUTC a one-time license fee of US$6,000 and committed to pay annual license maintenance fees of US$2,000. On July 10, 2023, the license was terminated and there are no further obligations. On October 7, 2025, the Company entered into a Memorandum of Understanding (“MOU”) with the Timiskaming First Nation (“TFN”) whose traditional lands include the area subject the Company’s and Quebec Innovative Materials Corp (see Note 9) exploration activities. The MOU establishes a framework for mutual cooperation between the parties with respect to TFN’s deep cultural, historical and spiritual connections to the land. The MOU also provides a commitment of the integration of TFN’s aboriginal traditional knowledge into environmental monitoring and project design. The Company will pay TFN an aggregate amount of $50,000 per annum over a three-year period.